Rocket Lab's Summer of Extremes: A Stock Down 36% While the Order Book Hits Records

Rocket Lab shares slide 36% in 30 sessions amid Iridium acquisition concerns, even as Q1 revenue jumps 63.5% and backlog hits $2.2B.

There is a peculiar disconnect playing out in Rocket Lab's share price right now. The stock closed Friday at €56.30, essentially flat on the day, yet that calm surface masks one of the most violent stretches in the company's recent trading history. Over the past 30 sessions, the equity has shed 36% of its value, and it now sits roughly 58% below the €133.80 peak reached on May 27. For long-term holders, the picture is less grim — shares remain up 39% year-over-year — but the recent slide has nonetheless rattled sentiment.

What makes the sell-off so striking is that it arrives alongside some of the strongest operational numbers the company has ever reported. The market, it seems, is pricing something other than the core business.

The Gap Between Price and Fundamentals

A persistent chasm has opened between where Rocket Lab trades and where Wall Street thinks it should be. Consensus price targets imply substantial upside from current levels, a divergence that rarely persists indefinitely without one side capitulating. That gap has widened considerably since June, when Rocket Lab unveiled plans to acquire Iridium Communications in a deal valued at roughly $8 billion. Questions about dilution and financing structure have weighed more heavily on the stock than the underlying business itself.

The fundamentals, for their part, tell a story of momentum. First-quarter fiscal 2026 revenue climbed to $200.35 million, a 63.5% year-over-year jump. The per-share loss of -$0.07 came in better than the -$0.0787 analysts had penciled in. The backlog has swelled to $2.2 billion, and on July 21 the company secured a $266 million contract with the US Space Force for suborbital launches — the largest defense award in its history, won against two competitors.

That military win was followed by another significant nod: the Space Force selected Rocket Lab among 15 companies, including Firefly Aerospace and Boeing, for a potential program worth up to $981 million. The company has also deepened its commercial ties, signing a multi-launch agreement with Japanese Earth-observation firm iQPS for three additional Electron missions beginning in late 2027, bringing the total contracted launches for that customer to 18. Each mission will deploy a QPS-SAR satellite into a 575-kilometer orbit, with iQPS relying on Rocket Lab's Motorized Lightband separation system. Electron has already delivered seven satellites for the constellation since 2023 with a perfect success rate.

The Iridium Bet: A Transformative Gamble

The Iridium acquisition represents a strategic pivot that extends well beyond the numbers. It would hand Rocket Lab immediate entry into IoT, direct-to-device communications, and security-related positioning services. Combined with Iridium's global network and L-band spectrum, the deal promises recurring, high-margin service revenue — a complement to Rocket Lab's launch and satellite manufacturing operations.

The financial logic is compelling on paper. Iridium generated $93 million in profit and $288 million in free cash flow over the past twelve months, while Rocket Lab posted a net loss of $183 million and negative cash flow of $316 million. Pro forma projections from Motley Fool suggest the combined entity could deliver $137 million in net income and $425 million in free cash flow by 2027, achieving sustained profitability for the first time. The transaction is expected to close in mid-2027.

Neutron: The Lingering Risk

The bear case rests primarily on the Neutron rocket program. The first launch is now targeted for the fourth quarter of 2026, pushed back after a tank test failure earlier in the year. A hydrostatic test mishap has eroded confidence in execution, and investors have responded by demanding a lower multiple. Yet the company retains room to absorb further setbacks: a full burn test of the second-stage AVac engine was completed in mid-July, marking meaningful progress toward the debut. With the $2.2 billion backlog providing cushion, the remaining test phases appear fundable.

A Broken Chart, An Overbought Debate

The technical picture offers little comfort to bulls. The stock trades roughly 32% below its 50-day moving average of €83.36, a pattern typically associated with a sustained downtrend. The RSI sits at 36.7, indicating oversold conditions without yet signaling a decisive reversal. Annualized 30-day volatility of 96.46% underscores just how violently sentiment has swung in both directions.

What August 10 Could Bring

All eyes now turn to August 10, when Rocket Lab reports second-quarter 2026 results. Analysts expect a loss of $0.06 per share on revenue of $231.62 million, a roughly 60% increase from the year-ago quarter. Options markets are pricing a 17% move in either direction — well above the average post-earnings swing of about 10.4% — suggesting traders anticipate fireworks.

Analyst opinions remain divided. Citizens' Trevor Walsh reaffirmed a Buy rating with a $130 price target, while KeyCorp upgraded the stock to Overweight with a $135 target. The broader consensus sits at a $110.29 average price target with a Moderate Buy rating. Institutional activity tells a mixed story: Dimensional Fund Advisors trimmed its stake by 8.1% in the first quarter, while Vanguard added 13.4% and Baillie Gifford increased its position by 47.2%.

Rocket Lab increasingly resembles a stock being punished for financing anxiety rather than operational failure. Revenue growth, record contracts, and Neutron progress all suggest the launch business is largely on track. It is the scale and structure of the Iridium deal — combined with Neutron's delay risk — that is driving the re-rating. Should Neutron slip again or the Iridium transaction collapse, the thesis would face serious strain. Absent those triggers, the argument for a mispriced sell-off holds more weight than that of a broken investment story. For those willing to tolerate elevated volatility, the gap between price and operational reality looks stretched — though the path to resolution is likely to remain bumpy until Neutron hits its milestones or Iridium details become clearer.